TrialPath

Find a study

Match me to a study

137 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

125 studies on the map

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — AMR Clinical, MobileA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) — AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, AvondaleA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain — MD First Research - Chandler, ChandlerAMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss — Pinnacle Research Group LLC, AnnistonA Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Arizona Research Center, Inc., PhoenixA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight — Cullman Clinical Trials, CullmanA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Pinnacle Research Group, AnnistonAMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Neighborhood Healthcare, EscondidoEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Headlands Research, ScottsdaleA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, GilbertMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Medical Dermatology Specialists, PhoenixA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes — MFA Clinical Research, TuscaloosaAMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Dignity Health, Mercy Gilbert, GilbertMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight — Neighborhood Healthcare, EscondidoAMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Univ of Alabama Birmingham, BirminghamConvergent Mechanisms Underlying Reprometabolic Syndrome in Women — University of Colorado School of Medicine, AuroraMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy — Valley Clinical Trials, NorthridgeA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Birmingham Clinical Research, BirminghamA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Birmingham Clinical Research, BirminghamEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — CenExel Anaheim Clinical Trials, AnaheimAMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Artemis Insitute for Clin Res, San DiegoEfficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes — Kailera Clinical Site, AnnistonAMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight — South Broward Research LLC, MiramarA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) — Carey Chronis MD Pediatric, Infant and Adolescent Medicine, VenturaA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Lakeview Clinical Research, GuntersvilleA Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Arizona Clinical Trials-Chandler, ChandlerA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerEfficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — Cahaba Research, Inc., PelhamA Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities — Carey Chronis MD Pediatric, Infant and Adolescent Medicine, VenturaMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Uni of Alabama at Birmingham, BirminghamEfficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes — Kailera Clinical Site, CullmanEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseEfficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes — Kailera Clinical Site, GlendaleA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerEfficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity — Kailera Clinical Site, ChandlerFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixA Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM — Clinical Trial Site, MontclairCaloric Restriction and Activity to Reduce Chemoresistance in B-ALL — Children's Hospital Los Angeles, Los AngelesProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss — DM Clinical Research - Phoenix, PhoenixA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerA Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity — Parexel International-EPCU Baltimore, BaltimoreA Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) — University of Alabama, BirminghamA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use — Vanda Investigational Site, Los AngelesA Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity — ClearVue Eye Care, RosevilleA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment — UAB Pediatric Endocrinology (Part C and Part D), BirminghamBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraTirzepatide in PWS, HO and GNSO — Children's Minnesota, Saint PaulOxytocin for Weight Loss in Adolescents — Massachusetts General Hospital, BostonMetformin IN Asthma for Overweight and Obese Individuals (MINA) — Johns Hopkins University, BaltimoreA Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity — Altasciences Clinical LA, Inc., CypressMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoA Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. — Monroe Biomedical Research, LouisvilleEfficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity — The Children's Hospital of Philadelphia, PhiladelphiaSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation — The University of Arizona College of Medicine- Phoenix, PhoenixSit Less, Interact and Move More (SLIMM) 2 Study — Stanford University, StanfordTesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV — University of Colorado - Anschutz Medical Campus, AuroraSocial Determinants and a Diabetes Prevention Program Tailored for African Americans — University Health, Kansas CitySemaglutide for Post-Smoking Cessation Weight Management — The University of Texas at Austin, AustinInvestigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism — Biomedical Research Imaging Center Marsico Hall (UNC), Chapel HillPhentermine's Impact on Treatment in Teens — University of New Mexico Health Sciences Center, AlbuquerqueSupplementing L-citrulline to Overweight Late Asthma oNset Phenotypes — Duke University (Asthma, Allergy and Airway Center), DurhamTirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity — Clinical and Translational Research Unit, Palo AltoWeight Loss Study: Genetics and Response to Naltrexone/Bupropion — Columbia University Medical Center, New YorkResistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity — St. Jude Children's Research Hospital, MemphisA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) — Children's Hospital Los Angeles, Los AngelesEffect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity — Massachusetts General Hospital, BostonA Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes — Altasciences Clinical Los Angeles, Inc., CypressFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaTirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors — Weill Cornell Medicine, New YorkPioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants — Texas Diabetes Institute/UH, San AntonioOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease — Cleveland Clinic Main Campus, ClevelandA Mobile Intervention to Reduce Pain and Improve Health-III — Wake Forest University, Winston-SalemVaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. — Inova Health System, Falls ChurchSingle Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects — Cedars Sinai Medical Center, Los AngelesAntibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 — University of Oklahoma Health Sciences Center, Oklahoma CityFasted vs. Fed State Exercise — Arkansas Colleges of Health Education Research Institure Health and Wellness Center, Fort SmithThe Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity — Mayo Clinic in Florida, JacksonvilleTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation — Cleveland Clinic, ClevelandPilot Testing a Novel Approach to Pediatric Obesity Treatment — Texas Tech University, LubbockPharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery — University of California Irvine Medical Center, OrangeIncretin Microdosing for Cardiometabolic Health in People With HIV — The University of Texas Health Science Center at Houston, HoustonThe Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action — Indiana University School of Medicine, IndianapolisGLP-1R Actions on Muscle and the Skeleton — Pennington Biomedical Research Center, Baton RougeDetermining the Optimal Amount of Structured Environments for Healthy Kids — University of South Carolina, ColumbiaBone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy — University of Virginia Medical Center, CharlottesvilleFood Prescriptions to Promote Affordable Diets — Kaiser Permanente, PasadenaFood-Body-Mind Intervention (16 Weeks) — Community Action Agency, Jackson2024 Tirzepatide-Bariatric Surgery — University of Kentucky, LexingtonSympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CityProject SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults — University of Minnesota, MinneapolisImpact GLP-1 Agonists Following Bariatric — University of Missouri Hospital, ColumbiaControl Systems Engineering for Weight Loss Maintenance — Miriam Hospital Weight Control and Diabetes Resarch Center, ProvidencePharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients — University of California San Diego, La JollaEffects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment — NIDDK, Phoenix, PhoenixPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioRole of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome — University of Colorado Anschutz/Children's Hospital Colorado Aurora, AuroraEffect of Ketone Esters on Liver Fat Content and Metabolic Function — Washington University School of Medicine, St LouisArterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity — Harry S. Truman Memorial, Columbia, MO, ColumbiaGlucagon-Like Peptide-1 Receptor Agonist in ADPKD — University of Colorado - Anschutz Medical Campus, AuroraTirzepatide for Alcohol Use Disorder — Keck School of Medicine, University of Southern California, Los AngelesEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraEfficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder — Johns Hopkins University, BaltimoreObesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment — Yale Pediatric Diabetes Center, Adult and Children's Progam, New HavenSympathetic Mechanisms in Obesity-Crossover Design — Vanderbilt University Medical Center, NashvilleA Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity — Drexel University, PhiladelphiaHealthy Kids Beyond the Bell: Investigating the Impact of After-School and Summer Programs — University of South Carolina, ColumbiaTaxi ROADmAP (Realizing Optimization Around Diet And Physical Activity) — Mexican Consulate's Ventanilla de Salud (VDS), New YorkA Novel Obesity Prevention Program for High-Risk Infants in Primary Care — Hopple Street Neighborhood Health Center, CincinnatiThe Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function — Vanderbilt University Medical Center, NashvilleAnti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma — University of Colorado Anschutz Medical Campus, AuroraIndividualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder — Mayo Clinic, RochesterThe Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics — University of Kentucky, LexingtonPolypill for Prevention of Cardiomyopathy — UT Southwestern Medical Center, DallasEquol and Vascular Function in Women With Chronic Kidney Disease — University of Colorado Anschutz Medical Campus, AuroraA Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease — Sarfez Pharmaceuticals, Inc., ViennaPulmonary Hypertension SOLAR — Duke University Medical Center, Durham